Yanhui Li*†, Su Dong*†, Arya Tamaskar†, Heather Wang†, Jing Zhao†, Haichun Ma*, Yutong Zhao†
Oncology Research, Vol.28, No.5, pp. 497-507, 2020, DOI:10.3727/096504020X15929939001042
Abstract Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for 85% of all
lung carcinomas. The hepatocyte growth factor receptor (c-Met) has been considered as a potential therapeutic target for NSCLC. Proteasome inhibition induces cell apoptosis and has been used as a novel therapeutic
approach for treating diseases including NSCLC; however, the effects of different proteasome inhibitors on
NSCLC have not been fully investigated. The aim of this study is to determine a precise strategy for treating
NSCLC by targeting c-Met using different proteasome inhibitors. Three proteasome inhibitors, bortezomib,… More >
Login
Register
